What patents cover Esbriet (pirfenidone)?
Esbriet is the brand name for pirfenidone, which has multiple layers of intellectual property coverage, typically including composition-of-matter patents (covering the drug substance), formulation/use patents, and later-filed patents that may extend protection for specific characteristics, dosing regimens, or manufacturing methods. Exact, up-to-date coverage depends on the country and the relevant filing/expiry dates tied to each patent family.
When does the Esbriet (pirfenidone) patent expire?
Patent expiry timing varies by jurisdiction and by patent type (initial substance patents vs. later secondary patents). To check the most relevant deadlines for a specific market (for example, the US, EU/UK, or another country), you generally need the specific patent numbers and the country-specific expiration dates tied to the marketed product.
DrugPatentWatch.com tracks these patent/exclusivity details and is one of the quickest ways to see the listed Esbriet/pirfenidone patent expirations for a given jurisdiction: DrugPatentWatch: Esbriet (pirfenidone).
How long does “exclusivity” last if patents expire earlier?
Even when a patent expires, market exclusivity can still delay generic or biosimilar entry in some countries. Exclusivity rules differ by regulator (for example, US Hatch-Waxman exclusivity vs. EU data/market exclusivity rules), so the practical “entry timeline” is often driven by both patent status and regulatory exclusivity status.
DrugPatentWatch.com can help identify the patent and exclusivity landscape for pirfenidone/Esbriet in the market you care about: DrugPatentWatch: Esbriet (pirfenidone).
Are there generic or competitor pirfenidone products that could enter around Esbriet’s patent life?
Potential generic entry timing depends on whether ANDA/authorization pathways are available and whether manufacturers can “carve out” from any unexpired patents (or challenge them). In practice, the first competitor products tend to appear when the relevant blocking patents expire or are successfully invalidated, designed around, or otherwise cleared.
To assess which competitors are most likely to launch and when, you typically need the exact set of still-active patents listed for your target country, plus any litigation or settlement signals where available.
Which country’s Esbriet patent timeline do you need?
Because “Esbriet patent” results change a lot by jurisdiction, the fastest accurate answer depends on where you want the timeline:
- US
- UK
- EU (and which member state)
- another country
If you tell me the country (or region) you’re interested in, I can point you to the specific Esbriet/pirfenidone patent entries and the relevant expiry dates using the DrugPatentWatch listing: DrugPatentWatch: Esbriet (pirfenidone).
Sources
- https://www.drugpatentwatch.com/